Physician profile
Nida Anees
NPI 1508561747
$6,057.88
in general payments reported to CMS, 2019-2025
26 companies · $2,213 in 2025
The $2,213 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,602 · 2024: $2,243 · 2025: $2,213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,776 · Education: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,776.29 |
| Education | $281.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,371.48 | 2023-2025 | |
| Janssen Biotech, INC. | $1,045.85 | 2023-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $668.71 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Ferring Pharmaceuticals INC. | $428.75 | 2023-2025 | Rebyota, Clenpiq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $346.05 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Aimmune Therapeutics, INC. | $302.32 | 2024-2025 | Zenpep, Vowst |
| Intercept Pharmaceuticals, INC. | $131.24 | 2023 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $124.01 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $77.28 | 2024 | Voquezna |
| Ardelyx, INC. | $69.42 | 2023-2024 | Ibsrela |
| Lilly USA, LLC | $67.83 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $61.68 | 2023-2024 | Linzess |
| Genzyme Corporation | $47.14 | 2023-2024 | |
| Nestle Healthcare Nutrition INC. | $44.51 | 2023 | |
| Braintree Laboratories, INC. | $37.35 | 2024 | Suflave |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $32.04 | 2023-2024 | Dificid |
| Pfizer INC. | $25.60 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.01 | 2024 | |
| Madrigal Pharmaceuticals | $22.30 | 2024 | Resmetirom |
| Ipsen Biopharmaceuticals, INC | $21.30 | 2025 | Iqirvo |
| Redhill Biopharma INC. | $20.35 | 2023 | Talicia |
| Enterra Medical, INC. | $19.14 | 2024 | |
| Celltrion USA INC. | $18.31 | 2023 | Yuflyma |
| Qol Medical, LLC | $18.06 | 2025 | Sucraid |
| Fresenius Kabi USA, LLC | $17.27 | 2023 | Idacio |
| Novo Nordisk INC | $16.88 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nida Anees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.